Asthma has been associated with increased cardiovascular disease (CVD) risk. The authors ascertained the association of asthma with CVD and the roles that sex, concurrent allergy, and asthma medications may play in this association. They assembled a cohort of 203,595 Northern California adults with asthma and a parallel asthma-free referent cohort (matched 1:1 on age, sex, and race/ethnicity); both cohorts were followed for incident nonfatal or fatal CVD and all-cause mortality from January 1, 1996, through December 31, 2008. Each cohort was 66% female and 47% white. After adjustment for age, sex, race/ethnicity, cardiac risk factors, and comorbid allergy, asthma was associated with a 1.40-fold (95% confidence interval (CI): 1.35, 1.45) increased hazard of coronary heart disease, a 1.20-fold (95% CI: 1.15, 1.25) hazard of cerebrovascular disease, a 2.14-fold (95% CI: 2.06, 2.22) hazard of heart failure, and a 3.28-fold (95% CI: 3.15, 3.41) hazard of all-cause mortality. Stronger associations were noted among women. Comorbid allergy predicted CVD but did not synergistically increase the CVD risk associated with asthma. Only asthma patients using asthma medications ( particularly those on oral corticosteroids alone or in combination) were at enhanced risk of CVD. In conclusion, asthma was prospectively associated with increased risk of major CVD. Modifying effects were noted for sex and asthma medication use but not for comorbid allergy.
Adult asthma, especially among women, is an independent predictor of increased risk for coronary heart disease (CHD), stroke, and cardiovascular disease (CVD) mortality (1) (2) (3) (4) (5) (6) (7) . Recent evidence indicates that common allergic symptoms are also associated with prevalent CHD (8) . However, none of these earlier investigations examined the relation of asthma with incident heart failure and the role that comorbid allergies and use of asthma medications may play in these relations.
Therefore, our aims in this study were to investigate the association between asthma and major CVD incidence (including CHD, cerebrovascular disease and its subtypes, and heart failure) and to assess whether prespecified subgroups (women, persons with concomitant allergy diagnoses, and persons using asthma medication-particularly combination therapy including systemic corticosteroids) may be at particularly elevated or reduced risk of CVD.
MATERIALS AND METHODS

Population and study design
We identified, retrospectively, a cohort of adult members of the Kaiser Permanente Northern California (KPNC) health-care plan with asthma (i.e., the "adult asthma cohort"; n = 203,595) and a referent cohort of KPNC members without asthma who were individually matched on age, sex, and race/ethnicity to the adult asthma cohort.
The criteria for inclusion in the adult asthma cohort were being aged 18 years or older and active membership in KPNC, plus evidence of health-care utilization for asthma between January 1, 1996, and December 31, 2006 . The definition of asthma health-care utilization included hospitalization with an International Classification of Diseases, Ninth Revision (ICD-9) (9) primary discharge code of 493.00-493.99 or at least 1 secondary code for asthma with a principal ICD-9 code for acute asthma-related respiratory conditions, or 2 or more outpatient visits for asthma within a 12-month period or 2 or more emergency department visits for asthma during a 12-month period. To avoid misclassification with chronic obstructive pulmonary disease, patients with utilization consistent with chronic obstructive pulmonary disease (ICD-9 code 492 or 496) within a 1-year period prior to baseline were excluded (baseline was defined as the first date on which the criteria for entry into the asthma cohort were met). This algorithm has been used extensively (10) (11) (12) and has been previously validated in the KPNC membership by medical record review (11, 13) . The Kaiser Foundation Research Institute institutional review board approved the study. The requirement that informed consent be obtained from study participants was waived because this was a data-only study.
Covariates
Prevalent diabetes, hypertension, CHD, stroke, heart failure, and allergic conditions were ascertained using relevant inpatient and outpatient ICD-9 and Current Procedural Terminology, Fourth Edition (14) , codes in KPNC electronic databases dating back to 1980, as was done previously (15, 16) . The allergy diagnoses included allergic rhinitis, dermatitis due to a food substance taken internally, allergic urticaria, angioneurotic edema, anaphylactic shock (due to an adverse food reaction, serum, sting, or other), and unspecified allergic reaction. ICD-9 codes for these allergic conditions are provided in Appendix Table 1 . Anaphylactic shock was validated by means of chart review in a prior study (16) . Body mass index and smoking status were ascertained using outpatient records preceding the index date (i.e., time 0) for up to 5 years (when more than 1 record existed, we used the most recent record). Use of cholesterol-lowering agents (as a proxy for hyperlipidemia) was ascertained by means of electronic pharmacy dispensing records indicating 1 or more active prescriptions during the period from 12 months prior to the index date through the end of follow-up (i.e., the first occurrence of a CVD event, death, or December 31, 2008) . Use of asthma medication at baseline and throughout follow-up was ascertained using electronic pharmacy dispensing records.
Statistical analysis
Time 0 (date of cohort entry or baseline) for the nonasthma cohort members was the same as the corresponding asthma subject's time 0, but each member of the pair could have been right-censored at different times, depending on incident events, vital status, or KPNC membership status. Beginning at time 0 for each subject, and separately for subjects in the adult asthma cohort and the nonasthma cohort, we calculated age-adjusted incidence rates ( per 100,000 person-years) of CHD and its subtypes, cerebrovascular disease and its subtypes, and heart failure. The ICD-9 and Current Procedural Terminology, Fourth Edition, codes used in outcome ascertainment are listed in Appendix Table 2 .
Prior longitudinal studies among KPNC members have demonstrated the validity of discharge diagnostic codes for myocardial infarction (17) , stroke (18, 19) , and heart failure (20) . However, because of potential misdiagnoses of heart failure as asthma and concerns about the validity of heart failure diagnoses in asthma, we conducted a medical record review of 31 (randomly selected) incident cases of heart failure that occurred in 2008/2009 among members of the asthma cohort identified in HealthConnect, Kaiser Permanente's fully electronic medical record. Of the 31 cases, 20 were confirmed as definite using the heart failure criteria of the CARDIA (Coronary Artery Risk Development in Young Adults) Study (21) . Of the remaining 11 cases, 1 patient had diastolic dysfunction as diagnosed by echocardiography, 6 had elevated B-type natriuretic peptide levels (ranging from 149 pg/mL to 1,319 pg/mL), 2 had a prior history of hospitalization for heart failure, and 2 had no biomarker or echocardiographic evidence of heart failure. Therefore, combining the 20 cases with definitive diagnoses with the 6 cases with elevated B-type natriuretic peptide levels and the 1 case with diastolic dysfunction diagnosed by echocardiography, 27 out of 31 cases (87%) were satisfactorily validated as cases of true heart failure. Two patients (6%) had a prior history of heart failure, and the diagnosis was carried forward to the hospitalization of interest; we failed to validate 2 additional cases (6%). Although the validation sample was small and confined to the later years of follow-up (and therefore potential uncertainties remain), our method of ascertaining incident heart failure appears to have been reliable.
To examine the association between asthma and the study outcomes, we employed conditional Cox proportional hazards models with asthma as the main independent variable (22) . To examine incidence, we excluded subjects with a prior history of the event of interest from the analysis; right-censoring was applied at the date of the first event, death, discontinuation of KPNC membership, or December 31, 2008, whichever came first. We fitted 3 sequential models: model 1, containing no covariates (age, sex, and race/ethnicity were controlled by means of the matched design); model 2, with adjustment for diabetes, hypertension, hyperlipidemia, body mass index, and smoking status; and model 3, which included adjustment for the model 2 covariates plus prior history of any allergy as a single dichotomous variable. We performed a priori subgroup analyses of study outcomes, stratifying by sex. We then tested the interactions between asthma and allergy and estimated the combined association of asthma and the presence of any concomitant allergy diagnoses with the hazard of CVD conditions (by creating a 4-level categorical variable: asthma with allergy, asthma without allergy, allergy with no asthma, and no asthma and no allergy (referent group)). Finally, to disentangle the effect of asthma per se from the effect of asthma medication use, we performed multivariable Cox regression categorizing asthma subjects into 2 groups according to asthma medication use, with noasthma subjects comprising the referent group. Moreover, to ascertain which asthma treatment modality might be responsible for the observed associations, we further subdivided treated patients with asthma into 3 mutually exclusive groups: 1) use of short-acting β agonists only; 2) use of another single therapy or any combination not including systemic corticosteroids; and 3) use of systemic corticosteroids or any combination including systemic corticosteroids, with no-asthma subjects as the referent group. All statistical analyses were carried out using SAS, version 9.13 (SAS Institute, Inc., Cary, North Carolina).
RESULTS
The adult asthma and nonasthma cohorts were 66% female, 47% white, 9% Asian, 8% Hispanic/Latino, 7% black, 4% mixed, and <1% Native American (Table 1) . In both cohorts, the mean age was 45 years (standard deviation, 16); 55% were under age 46 years and 13% were over age 64 years. The adult asthma cohort and the nonasthma cohort had similar prevalences of diabetes, hyperlipidemia, CHD, and cerebrovascular disease. On the other hand, the prevalences of hypertension and heart failure tended to be slightly higher among patients with asthma. History of allergy ( particularly history of allergic rhinitis but also other allergic conditions) was more than twice as common in the asthma cohort (40%) as in the nonasthma cohort (16%). Whereas 33% and 7% of participants were obese and morbidly obese, respectively, in the adult asthma cohort, the corresponding percentages in the nonasthma cohort were 28% and 4%. The prevalences of current and former smoking were similar in both cohorts. Seventy percent of asthma subjects were using short-acting β agonists, 50% inhaled corticosteroids, and 20% oral corticosteroids. The percentages using other classes of asthma medication were as follows: 5% long-acting β agonists, 6% anticholinergic agents, 1.5% leukotriene modifiers, and 5% xanthine derivatives. Table 2 presents the number of prospectively recorded events and the age-adjusted event rates per 100,000 personyears after a median of 5.2 years of follow-up (interquartile range, 2.3-8.6) among subjects with asthma and a median 6.3 years of follow-up (interquartile range, 3.3-9.3) among subjects without asthma. All rates were consistently higher Table 3 ).
among subjects with asthma than among subjects with no asthma. After adjustment for age, sex, and race/ethnicity, asthma was associated with significantly increased risk of all CVD conditions, with hazard ratios ranging from 1.15 (95% confidence interval: 1.10, 1.22) for a revascularization procedure to 2.33 (95% confidence interval: 2.25, 2.41) for heart failure (Table 3, model 1). After adjustment for diabetes, hypertension, hyperlipidemia, body mass index, and smoking status (Table 3 , model 2), the associations of asthma with revascularization procedures and subarachnoid hemorrhage were no longer statistically significant; hazard ratios for the other CVD outcomes were attenuated but remained significant. Further adjustment for history of any allergy diagnosis (Table 3 , model 3) did not change the risk estimates appreciably. In model 3, the strongest association of asthma with incident CVD was with heart failure (i.e., a 2.14-fold increased risk). Regardless of the level of adjustment, subjects with asthma were at more than 3-fold increased risk of all-cause mortality.
With the exception of subarachnoid hemorrhage, where the risk estimate associated with asthma was higher in men than in women (although not reaching statistical significance in any sex), all of the hazard ratios tended to be higher in women than in men (the asthma × sex interaction was statistically significant for all CHD conditions except revascularization procedure and for heart failure) ( Table 4 ).
The sex-stratified analysis also revealed that asthma was not associated with significantly increased risk of revascularization procedure and subarachnoid hemorrhage in either sex or with intracerebral hemorrhage and other cerebrovascular diseases in men. In addition, the fully adjusted relations of asthma with all-cause mortality were similar between the sexes (approximately 3-fold increased hazard). Table 5 shows results from analysis of the cardiovascular risks associated with asthma with and without a history of allergy, as well as the corresponding risk of allergy without asthma (relative to nonasthmatic subjects with no history of allergy), after adjustment for model 2 covariates. In these subgroup analyses, we focused on combined CHD, combined cerebrovascular disease, and heart failure. All of the risk relations were statistically significant, and in the cases of CHD and heart failure they tended to be stronger in the subgroup with asthma only, followed by the subgroup with asthma and history of allergy and then the subgroup with history of allergy only; the order was reversed for cerebrovascular disease. Allergy only was not related to increased all-cause mortality.
Whereas 16% of patients with asthma did not use any asthma medications, 84% used 1 or more. Compared with the referent cohort, persons not using asthma medication were at reduced risk of CHD, cerebrovascular disease, and heart failure but had a 4.2-fold increased hazard of allcause mortality (Table 6 ). By contrast, subjects using 1 or Table 3 ).
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Am J Epidemiol. 2012;176(11):1014-1024 more asthma medications were at increased risk of CHD, cerebrovascular disease, and heart failure and had a 2.4-fold increased hazard of all-cause mortality ( Table 6 ). The analyses stratifying asthma medication exposure into 3 mutually exclusive groups, relative to the nonasthma cohort, revealed that persons using short-acting β agonists only were at significantly reduced risk of CHD, cerebrovascular disease, and heart failure ( Table 7) . Use of oral corticosteroids, alone or in combination, was associated with greatly enhanced risk of CHD, cerebrovascular disease, and heart failure. Conversely, risks of all-cause mortality did not differ substantially across asthma treatment groups (Table 7) .
DISCUSSION
In this cohort study, we found that adult patients with asthma, relative to counterparts with no history of asthma, had increased risks of incident CHD, cerebrovascular disease, and heart failure. These associations of asthma with these major clinical CVD outcomes were independent of age, sex, race/ethnicity, and traditional risk factors, as well as history of allergy as a proxy for atopy. The strength of these associations varied from mild (i.e., hazard ratios of 1.13-1.18 for cerebrovascular disease outcomes) to moderate (hazard ratios between 1.29 and 1.36 for CHD outcomes) to strong (hazard ratio of 2.14 for heart failure).
A body of literature exists linking asthma and cardiovascular disease (2-7, 23, 24) . The current study differs from a prior Kaiser Permanente study (3) in several important ways: First, asthma was defined here using a validated utilization-based algorithm rather than self-reports; second, several CVD outcomes besides CHD (i.e., cerebrovascular disease and heart failure) were evaluated; and third, unlike the prior study, consideration was given to history of allergy and asthma medication use.
Several studies (3, 7, 24) previously found that the increased risk of CVD conferred by asthma was confined to women. In our study, we found stronger associations in women than in men, but there were clear increased risks of CHD, combined cerebrovascular disease, and heart failure among men. Our findings are consistent with experimental investigations showing that the pathogenesis of a variety of lung diseases is influenced by sex, suggesting that sex hormones play a crucial role in modulating immune response and chronic human lung diseases (25, 26) .
Another noteworthy finding was the lack of evidence of a positive synergistic effect of asthma and history of allergy on the risk of major CVD. Instead, we noted a significant effect of allergy with no asthma on the risk of combined CHD, combined cerebrovascular disease, and heart failure. These results are in agreement with recently published results among NHAHES III participants (Third National Health and Nutrition Examination Survey) indicating that common allergic symptoms were associated with prevalent CHD (8) . There is also evidence of an epidemiologic association between allergic rhinitis and hypertension, a known CVD risk factor (27) (28) (29) .
The mechanisms for the asthma-CVD epidemiologic association (common risk factors, systemic inflammation, or Table 3 ).
effect of asthma medications) remain unclear. There is mounting evidence that asthma is associated with obesity (30, 31) , particularly early in life (32, 33) . It is well established that lung function impairment is an independent predictor of cardiovascular events (34) (35) (36) . Another theory is that chronic airway inflammation may contribute to systemic inflammation and to vulnerability to vascular disease (37) (38) (39) . A recent report from the Women's Health Study indicated that self-reported asthma is independently associated with type 2 diabetes (40) . Another line of evidence indicates that cytokines that are up-regulated in asthma may promote migration and activation of inflammatory cells implicated in atherogenesis (41) (42) (43) . Our study demonstrated clear risk stratification according to asthma medication use at baseline and during follow-up, such that persons not taking any asthma medication were at reduced risk of CVD, albeit increased risk of all-cause mortality. On the other hand, persons taking 1 or more asthma medications ( particularly oral corticosteroids alone or in combination) were at enhanced risk of both CVD and allcause mortality.
The adverse cardiovascular effects of β agonists, including increased heart rate, prolonged corrected Q-T interval and potential for arrhythmia, and metabolic effects, including hypokalemia and enhanced glycogenolysis (and hence increase in plasma glucose level), are well-documented (44) . The use of inhaled and oral corticosteroids may be a marker of more severe asthma, and there is also evidence that younger asthmatics are less likely to receive inhaled corticosteroids (45) . Sustained administration of glucocorticoids can result in derangement of cortisol metabolism, including Cushing syndrome (46), a shift toward increased expression of intercellular adhesion molecule 1 (47) , and decreased serum vitamin D levels (48) , which in turn have been associated with excess cardiovascular disease (49) . Vitamin D is a recognized modulator of the immune response, which is required for an adequate physiologic response to inflammatory diseases and immune-system- Abbreviation: CI, confidence interval. a Hazard ratio relative to the referent cohort with no asthma, adjusted for model 3 covariates (see Table 3 ).
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The present study had also several limitations. First, the observational nature of the data limits causal inference. Second, we were unable to segregate asthma patients by disease onset (i.e., childhood vs. adulthood). Third, we recognize the limitation of missing data elements and rightcensoring due to some subjects' leaving the health plan (24% of asthma subjects and 10% of control subjects were right-censored because of termination of membership). Fourth, we did not have data on inflammatory mediators. Fifth, we did not have a physiologic measure of asthma severity (i.e., lung function data). Sixth, we recognize the potential misdiagnoses of heart failure as asthma. Lastly, our population represented the insured health-care market, and thus findings may not be representative of uninsured populations.
In summary, adults with asthma, particularly those using multiple medications, may be at increased risk of major CVD conditions. Health professionals should be aware of this connection and should closely scrutinize known CVD risk factors in this patient population. Moreover, future pharmacoepidemiologic studies should focus on clarifying potential CVD consequences of asthma medication use, and clinical trials of asthma therapies should take into account the potential increased risk of CVD among persons with asthma.
